Case report reveals immune-related adverse events including dysphagia in a woman with melanoma, suggesting close monitoring during Pembrolizumab treatment.
Key Points
This report describes the case of a 65-year-old woman developing Bulbar Myasthenic Syndrome during melanoma treatment.
Case report of a woman with melanoma receiving Pembrolizumab.
Assessment of symptoms including dysphagia, dysphonia, and ophthalmoplegia.
MRI and EMG conducted to evaluate neurological symptoms and muscle condition.
Patient experienced severe weakness and visual disturbances due to Bulbar Myasthenic Syndrome.
Creatine kinase was mildly elevated.
Treatment with IV Solumedrol, PLEX, and IVIG improved her respiratory status, allowing discharge.